# A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

> **NCT03338426** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 133 (actual)

## Conditions studied

- Essential Hypertension, Dyslipidemia

## Interventions

- **DRUG:** Fimasartan 120mg
- **DRUG:** Atorvastatin 40mg
- **DRUG:** Placebo for Fimasartan 120mg
- **DRUG:** Placebo for Atorvastatin 40mg

## Key facts

- **NCT ID:** NCT03338426
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2019-04-22
- **Final completion:** 2019-04-22
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338426, "A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03338426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*